Radiopharmaceuticals: Technologies and Global Markets
Report Highlights
The global market radiopharmaceuticals were valued at nearly $5.1 billion and $5.7 billion in 2014 and 2015, respectively. This market is expected to increase from nearly $6.5 billion in 2016 to $11.6 billion in 2021 at a compound annual growth rate (CAGR) of 12.4% for 2016-2021.
Report Includes
- An overview of the global market for radiopharmaceuticals and related technologies.
- Analyses of global market trends, with data from 2014 and 2015, 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Information on how radiopharmaceuticals are used to diagnose cancer, tumors, brain diseases, bone diseases, bone marrow diseases, colorectal disease, kidney diseases, liver diseases, lung diseases, and many others.
- Details concerning the regulatory environment and the impacts of government on the market.
- Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities
- Profiles of leading companies in the industry.
SCOPE OF THE STUDY
This report focuses on the global market for radiopharmaceutical products. Radiopharmaceuticals provide actual mapping of the physiological functions and metabolic activity of organs. They provide highly specific information on organ function and dysfunction. Radiopharmaceuticals can also be used in radiotherapy to destroy dysfunctional cells.
In this report, BCC Research analyzes each global market in terms of applications, regulatory environment, new products and advancements, market projections and market shares. The geographical regions covered in the report are North America and Europe and an emerging markets category. The emerging markets category covers countries that include India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand and Canada.
This report also includes an analysis of relevant patent and comprehensive profiles of leading companies in the radiopharmaceuticals industry. Some of the major global players in the radiopharmaceuticals industry are Advanced Medical Isotope Corp., Advanced Accelerator Applications SA, Bayer AG (Bayer HealthCare Pharmaceuticals Inc.), Bracco S.p.A. (Bracco Imaging S.p.A.), Cardinal Health Inc., Eli Lilly and Co., Fujifilm RI Pharma Co. Ltd. (Fujifilm Corp.), General Electric Co. (GE Healthcare), Jubilant Life Sciences (Jubilant DraxImage Inc.), Lantheus Holdings Inc. (Lantheus Medical Imaging Inc.), Mallinckrodt PLC, Navidea Biopharmaceuticals Inc., Noridon Inc., Piramal Enterprises Ltd. (Piramal Imaging SA), Siemens AG (Siemens PETNET Solutions Inc.) and Triad Isotopes Inc.
Frequently Asked Questions (FAQs)
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
Report Highlights
The global market for radiopharmaceuticals in 2012 was about $3.8 billion and $3.9 billion in 2013. The estimated market for the year 2014 is nearly $4.4 billion and this figure is forecast to expand through 2019 at a projected compound annual growth rate (CAGR) of 8%, approaching $6.4 billion.
Report Includes
- An overview of the global market for radiopharmaceuticals and related technologies.
- Analyses of global market trends, with data from 2012 and 2013, estimates for 2014, and projections of CAGRs through 2019.
- Information on how radiopharmaceuticals are used to diagnose cancer, tumors, brain diseases, bone diseases, bone marrow diseases, colorectal disease, kidney diseases, liver diseases, lung diseases, and many others.
- Details concerning the regulatory environment and the impacts of government on the market.
- Profiles of leading companies in the industry.